Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF)
$ 0.1705 -0.0095 (-5.28%) Market Cap: 54.42 Mil Enterprise Value: 32.43 Mil PE Ratio: 0 PB Ratio: 2.45 GF Score: 29/100

Paradigm Biopharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 - Jan 13, 2022 / NTS GMT
Release Date Price: $1.44
Seth Schwartz
JPMorgan Chase & Co. - Moderator

Well, good morning and good afternoon, everyone. Welcome to the Paradigm Biopharmaceutical presentation. By way of background and introduction, my name is Seth Schwartz; I'm the Managing Director and Head of JPMorgan's Healthcare Investment Banking practice here in Australia. It gives me great honor to introduce Donna Skerrett, who is the Interim CEO of Paradigm and will lead today's presentation.

So with that, over to you, Donna.

Donna Skerrett
Paradigm Biopharmaceuticals Ltd. - Chief Medical Officer & Interim CEO

Thank you. Can I have the next slide, please? Paradigm is a publicly traded company. So please note the disclaimer. Thank you. Next slide.

I'd like to tell you a little bit about Paradigm. We're an Australian company founded in 2014, listed on the Exchange in 2015. And our objective is to repurpose agents, and we aim to develop new solutions for medical indications with high unmet need by repurposing underutilized molecules.

Our lead candidate is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot